EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy

被引:146
作者
Freudlsperger, Christian [1 ,2 ]
Burnett, Jeffrey R. [1 ]
Friedman, Jay A. [1 ]
Kannabiran, Vishnu R. [1 ]
Chen, Zhong [1 ]
Van Waes, Carter [1 ]
机构
[1] Natl Inst Deafness & Other Commun Disorders, Head & Neck Surg Branch, NIH, Bethesda, MD 20892 USA
[2] Univ Heidelberg Hosp, Dept Oral & Maxillofacial Surg, Heidelnberg, Germany
关键词
Akt; EGFR; head and neck squamous cell carcinoma; mTOR; PI3K; targeted therapy; GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE CK2; MULTICENTER PHASE-II; ANTITUMOR-ACTIVITY; PHOSPHOINOSITIDE; 3-KINASE; HEAT-SHOCK-PROTEIN-90; INHIBITOR; REPEAT POLYMORPHISM; MAMMALIAN TARGET; PIK3CA MUTATIONS; POTENT INHIBITOR;
D O I
10.1517/14728222.2011.541440
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Recent advances in the understanding of the oncogenesis of head and neck squamous cell carcinomas (HNSCC) have revealed multiple dysregulated signaling pathways. One frequently altered axis is the EGFR-PI3K-Akt-mTOR pathway. This pathway plays a central role in numerous cellular processes including metabolism, cell growth, apoptosis, survival and differentiation, which ultimately contributes to HNSCC progression. Areas covered in this review: Books, journals, databases and websites have been searched to provide a current review on the subject. What the reader will gain: This article reviews the current understanding of EGFR-PI3K-Akt-mTOR signaling in HNSCC, including the impact of both genetic and epigenetic alterations. This review further highlights the potential of targeting this signaling cascade as a promising therapeutic approach in the treatment of HNSCC. Take home message: Genetic alterations of several nodes within this pathway, including both genetic and epigenetic changes, leading to either oncogene activation or inactivation of tumor suppressors have frequently been implicated in HNSCC. Consequently, drugs that target the central nodes of this pathway have become attractive for molecular oriented cancer therapies. Numerous preclinical and clinical studies are being performed in HNSCC; however, more studies are still needed to better understand the biology of this pathway.
引用
收藏
页码:63 / 74
页数:12
相关论文
共 118 条
[1]  
AKINAGA S, 1991, CANCER RES, V51, P4888
[2]   An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors [J].
Amador, ML ;
Oppenheimer, D ;
Perea, S ;
Maitra, A ;
Cusati, G ;
Iacobuzio-Donahue, C ;
Baker, SD ;
Ashfaq, R ;
Takimoto, C ;
Forastiere, A ;
Hidalgo, M .
CANCER RESEARCH, 2004, 64 (24) :9139-9143
[3]   Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck [J].
Amornphimoltham, P ;
Patel, V ;
Sodhi, A ;
Nikitakis, NG ;
Sauk, JJ ;
Sausville, EA ;
Molinolo, AA ;
Gutkind, JS .
CANCER RESEARCH, 2005, 65 (21) :9953-9961
[4]   Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01 [J].
Amornphimoltham, P ;
Sriuranpong, V ;
Patel, V ;
Benavides, F ;
Conti, CJ ;
Sauk, J ;
Sausville, EA ;
Molinolo, AA ;
Gutkind, JS .
CLINICAL CANCER RESEARCH, 2004, 10 (12) :4029-4037
[5]  
[Anonymous], J CLIN ONCOL S
[6]   A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer [J].
Argiris, Athanassios ;
Cohen, Ezra ;
Karrison, Theodore ;
Esparaz, Benjamin ;
Mauer, Ann ;
Ansari, Rafat ;
Wong, Stuart ;
Lu, Yi ;
Pins, Michael ;
Dancey, Janet ;
Vokes, Everett .
CANCER BIOLOGY & THERAPY, 2006, 5 (07) :766-770
[7]   Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models [J].
Banerji, U ;
Walton, M ;
Raynaud, F ;
Grimshaw, R ;
Kelland, L ;
Valenti, M ;
Judson, I ;
Workman, P .
CLINICAL CANCER RESEARCH, 2005, 11 (19) :7023-7032
[8]   Heat Shock Protein 90 as a Drug Target: Some Like It Hot [J].
Banerji, Udai .
CLINICAL CANCER RESEARCH, 2009, 15 (01) :9-14
[9]   Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors [J].
Bianco, R ;
Shin, I ;
Ritter, CA ;
Yakes, FM ;
Basso, A ;
Rosen, N ;
Tsurutani, J ;
Dennis, PA ;
Mills, GB ;
Arteaga, CL .
ONCOGENE, 2003, 22 (18) :2812-2822
[10]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578